nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—XDH—Azathioprine—systemic scleroderma	0.336	0.546	CbGbCtD
Trifluoperazine—CYP1A2—Pentoxifylline—systemic scleroderma	0.0606	0.0983	CbGbCtD
Trifluoperazine—CYP1A2—Leflunomide—systemic scleroderma	0.0578	0.0938	CbGbCtD
Trifluoperazine—ABCB1—Lisinopril—systemic scleroderma	0.053	0.086	CbGbCtD
Trifluoperazine—ABCB1—Captopril—systemic scleroderma	0.0397	0.0644	CbGbCtD
Trifluoperazine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0312	0.0507	CbGbCtD
Trifluoperazine—ABCB1—Prednisone—systemic scleroderma	0.025	0.0405	CbGbCtD
Trifluoperazine—ABCB1—Methotrexate—systemic scleroderma	0.0125	0.0203	CbGbCtD
Trifluoperazine—HTR2A—myenteric nerve plexus—systemic scleroderma	0.00765	0.0723	CbGeAlD
Trifluoperazine—HTR2A—pulmonary artery—systemic scleroderma	0.00542	0.0512	CbGeAlD
Trifluoperazine—S100A4—connective tissue—systemic scleroderma	0.00459	0.0434	CbGeAlD
Trifluoperazine—S100A4—smooth muscle tissue—systemic scleroderma	0.0042	0.0397	CbGeAlD
Trifluoperazine—S100A4—skin of body—systemic scleroderma	0.00415	0.0392	CbGeAlD
Trifluoperazine—TNNC1—connective tissue—systemic scleroderma	0.00387	0.0366	CbGeAlD
Trifluoperazine—EBPL—lung—systemic scleroderma	0.00351	0.0332	CbGeAlD
Trifluoperazine—S100A4—Desoximetasone—Mometasone—systemic scleroderma	0.00343	0.647	CbGdCrCtD
Trifluoperazine—S100A4—digestive system—systemic scleroderma	0.00332	0.0314	CbGeAlD
Trifluoperazine—CALM2—artery—systemic scleroderma	0.00331	0.0313	CbGeAlD
Trifluoperazine—CALM1—artery—systemic scleroderma	0.0033	0.0312	CbGeAlD
Trifluoperazine—S100A4—tendon—systemic scleroderma	0.00316	0.0298	CbGeAlD
Trifluoperazine—UGT1A4—digestive system—systemic scleroderma	0.00291	0.0275	CbGeAlD
Trifluoperazine—CALM2—endothelium—systemic scleroderma	0.0028	0.0264	CbGeAlD
Trifluoperazine—CALM1—endothelium—systemic scleroderma	0.00278	0.0263	CbGeAlD
Trifluoperazine—S100A4—lung—systemic scleroderma	0.00277	0.0262	CbGeAlD
Trifluoperazine—TNNC1—tendon—systemic scleroderma	0.00266	0.0251	CbGeAlD
Trifluoperazine—CALM2—blood vessel—systemic scleroderma	0.00258	0.0244	CbGeAlD
Trifluoperazine—CALM1—blood vessel—systemic scleroderma	0.00257	0.0243	CbGeAlD
Trifluoperazine—TNNC1—lung—systemic scleroderma	0.00233	0.022	CbGeAlD
Trifluoperazine—XDH—digestive system—systemic scleroderma	0.00213	0.0201	CbGeAlD
Trifluoperazine—HTR2A—artery—systemic scleroderma	0.00201	0.019	CbGeAlD
Trifluoperazine—S100A4—Desoximetasone—Prednisone—systemic scleroderma	0.00187	0.353	CbGdCrCtD
Trifluoperazine—HTR2A—endothelium—systemic scleroderma	0.0017	0.016	CbGeAlD
Trifluoperazine—HTR2A—blood vessel—systemic scleroderma	0.00156	0.0148	CbGeAlD
Trifluoperazine—CALM3—smooth muscle tissue—systemic scleroderma	0.00154	0.0146	CbGeAlD
Trifluoperazine—SIGMAR1—smooth muscle tissue—systemic scleroderma	0.00138	0.013	CbGeAlD
Trifluoperazine—CALM2—connective tissue—systemic scleroderma	0.00132	0.0125	CbGeAlD
Trifluoperazine—CALM1—connective tissue—systemic scleroderma	0.00132	0.0124	CbGeAlD
Trifluoperazine—CALM2—smooth muscle tissue—systemic scleroderma	0.00121	0.0114	CbGeAlD
Trifluoperazine—CALM1—smooth muscle tissue—systemic scleroderma	0.0012	0.0114	CbGeAlD
Trifluoperazine—CALM2—skin of body—systemic scleroderma	0.00119	0.0113	CbGeAlD
Trifluoperazine—CALM1—skin of body—systemic scleroderma	0.00119	0.0112	CbGeAlD
Trifluoperazine—CALM3—tendon—systemic scleroderma	0.00116	0.0109	CbGeAlD
Trifluoperazine—SIGMAR1—tendon—systemic scleroderma	0.00103	0.00978	CbGeAlD
Trifluoperazine—ABCB1—blood vessel—systemic scleroderma	0.00102	0.00969	CbGeAlD
Trifluoperazine—CALM3—lung—systemic scleroderma	0.00102	0.0096	CbGeAlD
Trifluoperazine—HRH1—connective tissue—systemic scleroderma	0.00096	0.00908	CbGeAlD
Trifluoperazine—CALM2—digestive system—systemic scleroderma	0.000955	0.00903	CbGeAlD
Trifluoperazine—CALM1—digestive system—systemic scleroderma	0.000951	0.00899	CbGeAlD
Trifluoperazine—CALM2—tendon—systemic scleroderma	0.000909	0.00859	CbGeAlD
Trifluoperazine—SIGMAR1—lung—systemic scleroderma	0.000908	0.00858	CbGeAlD
Trifluoperazine—CALM1—tendon—systemic scleroderma	0.000905	0.00855	CbGeAlD
Trifluoperazine—HRH1—smooth muscle tissue—systemic scleroderma	0.000878	0.0083	CbGeAlD
Trifluoperazine—HTR2A—connective tissue—systemic scleroderma	0.000802	0.00758	CbGeAlD
Trifluoperazine—CALM2—lung—systemic scleroderma	0.000798	0.00754	CbGeAlD
Trifluoperazine—CALM1—lung—systemic scleroderma	0.000794	0.00751	CbGeAlD
Trifluoperazine—CYP1A2—digestive system—systemic scleroderma	0.000741	0.007	CbGeAlD
Trifluoperazine—HTR2A—smooth muscle tissue—systemic scleroderma	0.000734	0.00693	CbGeAlD
Trifluoperazine—DRD2—lung—systemic scleroderma	0.000733	0.00693	CbGeAlD
Trifluoperazine—Dyspnoea—Pentoxifylline—systemic scleroderma	0.000696	0.00288	CcSEcCtD
Trifluoperazine—Somnolence—Pentoxifylline—systemic scleroderma	0.000695	0.00287	CcSEcCtD
Trifluoperazine—HRH1—digestive system—systemic scleroderma	0.000694	0.00656	CbGeAlD
Trifluoperazine—Dry mouth—Mometasone—systemic scleroderma	0.000688	0.00285	CcSEcCtD
Trifluoperazine—Vision blurred—Captopril—systemic scleroderma	0.000684	0.00283	CcSEcCtD
Trifluoperazine—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.000681	0.00282	CcSEcCtD
Trifluoperazine—Decreased appetite—Pentoxifylline—systemic scleroderma	0.000679	0.00281	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Lisinopril—systemic scleroderma	0.000679	0.00281	CcSEcCtD
Trifluoperazine—Oedema peripheral—Leflunomide—systemic scleroderma	0.000677	0.0028	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Mometasone—systemic scleroderma	0.000674	0.00279	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Lisinopril—systemic scleroderma	0.000673	0.00279	CcSEcCtD
Trifluoperazine—Weight increased—Lisinopril—systemic scleroderma	0.000671	0.00278	CcSEcCtD
Trifluoperazine—Constipation—Pentoxifylline—systemic scleroderma	0.000668	0.00276	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Lisinopril—systemic scleroderma	0.000665	0.00275	CcSEcCtD
Trifluoperazine—Angioedema—Captopril—systemic scleroderma	0.000663	0.00274	CcSEcCtD
Trifluoperazine—HRH1—tendon—systemic scleroderma	0.00066	0.00624	CbGeAlD
Trifluoperazine—Muscular weakness—Mycophenolate mofetil—systemic scleroderma	0.000659	0.00273	CcSEcCtD
Trifluoperazine—Asthma—Mycophenolate mofetil—systemic scleroderma	0.000646	0.00267	CcSEcCtD
Trifluoperazine—Dysphagia—Mycophenolate mofetil—systemic scleroderma	0.000646	0.00267	CcSEcCtD
Trifluoperazine—Oedema peripheral—Mycophenolic acid—systemic scleroderma	0.000645	0.00267	CcSEcCtD
Trifluoperazine—Anorexia—Mometasone—systemic scleroderma	0.000643	0.00266	CcSEcCtD
Trifluoperazine—Jaundice—Lisinopril—systemic scleroderma	0.000641	0.00265	CcSEcCtD
Trifluoperazine—Cough—Captopril—systemic scleroderma	0.000633	0.00262	CcSEcCtD
Trifluoperazine—Urticaria—Pentoxifylline—systemic scleroderma	0.000621	0.00257	CcSEcCtD
Trifluoperazine—CYP1A2—lung—systemic scleroderma	0.000619	0.00585	CbGeAlD
Trifluoperazine—Body temperature increased—Pentoxifylline—systemic scleroderma	0.000618	0.00256	CcSEcCtD
Trifluoperazine—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.000614	0.00254	CcSEcCtD
Trifluoperazine—Agranulocytosis—Lisinopril—systemic scleroderma	0.000614	0.00254	CcSEcCtD
Trifluoperazine—Dry mouth—Captopril—systemic scleroderma	0.000604	0.0025	CcSEcCtD
Trifluoperazine—Dyspnoea—Mometasone—systemic scleroderma	0.000601	0.00249	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Mycophenolate mofetil—systemic scleroderma	0.000595	0.00246	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Captopril—systemic scleroderma	0.000592	0.00245	CcSEcCtD
Trifluoperazine—Weight increased—Mycophenolate mofetil—systemic scleroderma	0.000588	0.00243	CcSEcCtD
Trifluoperazine—Decreased appetite—Mometasone—systemic scleroderma	0.000586	0.00243	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	0.000583	0.00241	CcSEcCtD
Trifluoperazine—Oedema peripheral—Lisinopril—systemic scleroderma	0.000581	0.00241	CcSEcCtD
Trifluoperazine—Fatigue—Mometasone—systemic scleroderma	0.000581	0.00241	CcSEcCtD
Trifluoperazine—HTR2A—digestive system—systemic scleroderma	0.000579	0.00548	CbGeAlD
Trifluoperazine—HRH1—lung—systemic scleroderma	0.000579	0.00547	CbGeAlD
Trifluoperazine—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000576	0.00238	CcSEcCtD
Trifluoperazine—Muscle spasms—Leflunomide—systemic scleroderma	0.000575	0.00238	CcSEcCtD
Trifluoperazine—Leukopenia—Azathioprine—systemic scleroderma	0.000567	0.00235	CcSEcCtD
Trifluoperazine—Anorexia—Captopril—systemic scleroderma	0.000564	0.00234	CcSEcCtD
Trifluoperazine—Vision blurred—Leflunomide—systemic scleroderma	0.000563	0.00233	CcSEcCtD
Trifluoperazine—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.000561	0.00232	CcSEcCtD
Trifluoperazine—Asthenia—Pentoxifylline—systemic scleroderma	0.000561	0.00232	CcSEcCtD
Trifluoperazine—Nervousness—Mycophenolic acid—systemic scleroderma	0.000554	0.00229	CcSEcCtD
Trifluoperazine—Hypotension—Captopril—systemic scleroderma	0.000553	0.00229	CcSEcCtD
Trifluoperazine—Pruritus—Pentoxifylline—systemic scleroderma	0.000553	0.00229	CcSEcCtD
Trifluoperazine—HTR2A—tendon—systemic scleroderma	0.000551	0.00521	CbGeAlD
Trifluoperazine—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.000548	0.00227	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Methotrexate—systemic scleroderma	0.000548	0.00227	CcSEcCtD
Trifluoperazine—Angioedema—Leflunomide—systemic scleroderma	0.000546	0.00226	CcSEcCtD
Trifluoperazine—Increased appetite—Prednisone—systemic scleroderma	0.000539	0.00223	CcSEcCtD
Trifluoperazine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.000538	0.00222	CcSEcCtD
Trifluoperazine—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.000538	0.00222	CcSEcCtD
Trifluoperazine—Insomnia—Captopril—systemic scleroderma	0.000535	0.00222	CcSEcCtD
Trifluoperazine—Leukopenia—Leflunomide—systemic scleroderma	0.000535	0.00222	CcSEcCtD
Trifluoperazine—Tremor—Mycophenolic acid—systemic scleroderma	0.000534	0.00221	CcSEcCtD
Trifluoperazine—Body temperature increased—Mometasone—systemic scleroderma	0.000533	0.00221	CcSEcCtD
Trifluoperazine—Dyspnoea—Captopril—systemic scleroderma	0.000528	0.00218	CcSEcCtD
Trifluoperazine—Somnolence—Captopril—systemic scleroderma	0.000526	0.00218	CcSEcCtD
Trifluoperazine—Agitation—Mycophenolic acid—systemic scleroderma	0.000524	0.00217	CcSEcCtD
Trifluoperazine—Gynaecomastia—Methotrexate—systemic scleroderma	0.000522	0.00216	CcSEcCtD
Trifluoperazine—Cough—Leflunomide—systemic scleroderma	0.000522	0.00216	CcSEcCtD
Trifluoperazine—Dizziness—Pentoxifylline—systemic scleroderma	0.000517	0.00214	CcSEcCtD
Trifluoperazine—Decreased appetite—Captopril—systemic scleroderma	0.000515	0.00213	CcSEcCtD
Trifluoperazine—Erythema—Lisinopril—systemic scleroderma	0.000514	0.00213	CcSEcCtD
Trifluoperazine—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000511	0.00211	CcSEcCtD
Trifluoperazine—Fatigue—Captopril—systemic scleroderma	0.00051	0.00211	CcSEcCtD
Trifluoperazine—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.000509	0.00211	CcSEcCtD
Trifluoperazine—Constipation—Captopril—systemic scleroderma	0.000506	0.0021	CcSEcCtD
Trifluoperazine—Skin disorder—Azathioprine—systemic scleroderma	0.000502	0.00208	CcSEcCtD
Trifluoperazine—Nervousness—Lisinopril—systemic scleroderma	0.000499	0.00207	CcSEcCtD
Trifluoperazine—Dry mouth—Leflunomide—systemic scleroderma	0.000498	0.00206	CcSEcCtD
Trifluoperazine—Cough—Mycophenolic acid—systemic scleroderma	0.000498	0.00206	CcSEcCtD
Trifluoperazine—Convulsion—Mycophenolic acid—systemic scleroderma	0.000494	0.00205	CcSEcCtD
Trifluoperazine—Muscle spasms—Lisinopril—systemic scleroderma	0.000494	0.00204	CcSEcCtD
Trifluoperazine—Rash—Pentoxifylline—systemic scleroderma	0.000493	0.00204	CcSEcCtD
Trifluoperazine—Dermatitis—Pentoxifylline—systemic scleroderma	0.000492	0.00204	CcSEcCtD
Trifluoperazine—Headache—Pentoxifylline—systemic scleroderma	0.000489	0.00203	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000488	0.00202	CcSEcCtD
Trifluoperazine—Vision blurred—Lisinopril—systemic scleroderma	0.000484	0.002	CcSEcCtD
Trifluoperazine—HTR2A—lung—systemic scleroderma	0.000484	0.00457	CbGeAlD
Trifluoperazine—Asthenia—Mometasone—systemic scleroderma	0.000484	0.002	CcSEcCtD
Trifluoperazine—Hypotension—Azathioprine—systemic scleroderma	0.000483	0.002	CcSEcCtD
Trifluoperazine—Photosensitivity—Methotrexate—systemic scleroderma	0.000482	0.002	CcSEcCtD
Trifluoperazine—Cardiac arrest—Prednisone—systemic scleroderma	0.000482	0.00199	CcSEcCtD
Trifluoperazine—Tremor—Lisinopril—systemic scleroderma	0.000481	0.00199	CcSEcCtD
Trifluoperazine—Pruritus—Mometasone—systemic scleroderma	0.000477	0.00197	CcSEcCtD
Trifluoperazine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000475	0.00197	CcSEcCtD
Trifluoperazine—Skin disorder—Leflunomide—systemic scleroderma	0.000474	0.00196	CcSEcCtD
Trifluoperazine—Angioedema—Lisinopril—systemic scleroderma	0.000469	0.00194	CcSEcCtD
Trifluoperazine—Body temperature increased—Captopril—systemic scleroderma	0.000468	0.00194	CcSEcCtD
Trifluoperazine—Anorexia—Leflunomide—systemic scleroderma	0.000465	0.00193	CcSEcCtD
Trifluoperazine—Nausea—Pentoxifylline—systemic scleroderma	0.000464	0.00192	CcSEcCtD
Trifluoperazine—Leukopenia—Lisinopril—systemic scleroderma	0.00046	0.0019	CcSEcCtD
Trifluoperazine—Hypotension—Leflunomide—systemic scleroderma	0.000456	0.00189	CcSEcCtD
Trifluoperazine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000452	0.00187	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000449	0.00186	CcSEcCtD
Trifluoperazine—Cough—Lisinopril—systemic scleroderma	0.000448	0.00186	CcSEcCtD
Trifluoperazine—Muscular weakness—Prednisone—systemic scleroderma	0.000447	0.00185	CcSEcCtD
Trifluoperazine—Anorexia—Mycophenolic acid—systemic scleroderma	0.000444	0.00184	CcSEcCtD
Trifluoperazine—Insomnia—Leflunomide—systemic scleroderma	0.000441	0.00183	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000437	0.00181	CcSEcCtD
Trifluoperazine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.000437	0.00181	CcSEcCtD
Trifluoperazine—Dyspnoea—Leflunomide—systemic scleroderma	0.000435	0.0018	CcSEcCtD
Trifluoperazine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000435	0.0018	CcSEcCtD
Trifluoperazine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000433	0.00179	CcSEcCtD
Trifluoperazine—Dry mouth—Lisinopril—systemic scleroderma	0.000428	0.00177	CcSEcCtD
Trifluoperazine—Rash—Mometasone—systemic scleroderma	0.000425	0.00176	CcSEcCtD
Trifluoperazine—Asthenia—Captopril—systemic scleroderma	0.000425	0.00176	CcSEcCtD
Trifluoperazine—Dermatitis—Mometasone—systemic scleroderma	0.000425	0.00176	CcSEcCtD
Trifluoperazine—Decreased appetite—Leflunomide—systemic scleroderma	0.000424	0.00176	CcSEcCtD
Trifluoperazine—Headache—Mometasone—systemic scleroderma	0.000422	0.00175	CcSEcCtD
Trifluoperazine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000422	0.00175	CcSEcCtD
Trifluoperazine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000421	0.00174	CcSEcCtD
Trifluoperazine—Fatigue—Leflunomide—systemic scleroderma	0.000421	0.00174	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000419	0.00174	CcSEcCtD
Trifluoperazine—Pruritus—Captopril—systemic scleroderma	0.000419	0.00173	CcSEcCtD
Trifluoperazine—Constipation—Leflunomide—systemic scleroderma	0.000417	0.00173	CcSEcCtD
Trifluoperazine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000415	0.00172	CcSEcCtD
Trifluoperazine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000414	0.00171	CcSEcCtD
Trifluoperazine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000414	0.00171	CcSEcCtD
Trifluoperazine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000411	0.0017	CcSEcCtD
Trifluoperazine—Body temperature increased—Azathioprine—systemic scleroderma	0.000408	0.00169	CcSEcCtD
Trifluoperazine—Skin disorder—Lisinopril—systemic scleroderma	0.000407	0.00169	CcSEcCtD
Trifluoperazine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000405	0.00167	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Prednisone—systemic scleroderma	0.000403	0.00167	CcSEcCtD
Trifluoperazine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000403	0.00167	CcSEcCtD
Trifluoperazine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000401	0.00166	CcSEcCtD
Trifluoperazine—Nausea—Mometasone—systemic scleroderma	0.0004	0.00166	CcSEcCtD
Trifluoperazine—Anorexia—Lisinopril—systemic scleroderma	0.0004	0.00165	CcSEcCtD
Trifluoperazine—Weight increased—Prednisone—systemic scleroderma	0.000399	0.00165	CcSEcCtD
Trifluoperazine—Constipation—Mycophenolic acid—systemic scleroderma	0.000398	0.00165	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Prednisone—systemic scleroderma	0.000395	0.00163	CcSEcCtD
Trifluoperazine—Cough—Mycophenolate mofetil—systemic scleroderma	0.000393	0.00163	CcSEcCtD
Trifluoperazine—Hypotension—Lisinopril—systemic scleroderma	0.000392	0.00162	CcSEcCtD
Trifluoperazine—Dizziness—Captopril—systemic scleroderma	0.000392	0.00162	CcSEcCtD
Trifluoperazine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00039	0.00161	CcSEcCtD
Trifluoperazine—Urticaria—Leflunomide—systemic scleroderma	0.000388	0.0016	CcSEcCtD
Trifluoperazine—Body temperature increased—Leflunomide—systemic scleroderma	0.000386	0.0016	CcSEcCtD
Trifluoperazine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000381	0.00158	CcSEcCtD
Trifluoperazine—ABCB1—digestive system—systemic scleroderma	0.00038	0.00359	CbGeAlD
Trifluoperazine—Insomnia—Lisinopril—systemic scleroderma	0.000379	0.00157	CcSEcCtD
Trifluoperazine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000375	0.00155	CcSEcCtD
Trifluoperazine—Dyspnoea—Lisinopril—systemic scleroderma	0.000374	0.00155	CcSEcCtD
Trifluoperazine—Rash—Captopril—systemic scleroderma	0.000373	0.00155	CcSEcCtD
Trifluoperazine—Dermatitis—Captopril—systemic scleroderma	0.000373	0.00154	CcSEcCtD
Trifluoperazine—Somnolence—Lisinopril—systemic scleroderma	0.000373	0.00154	CcSEcCtD
Trifluoperazine—Headache—Captopril—systemic scleroderma	0.000371	0.00154	CcSEcCtD
Trifluoperazine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000368	0.00152	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000367	0.00152	CcSEcCtD
Trifluoperazine—Asthma—Methotrexate—systemic scleroderma	0.000366	0.00151	CcSEcCtD
Trifluoperazine—Decreased appetite—Lisinopril—systemic scleroderma	0.000364	0.00151	CcSEcCtD
Trifluoperazine—Eosinophilia—Methotrexate—systemic scleroderma	0.000362	0.0015	CcSEcCtD
Trifluoperazine—Fatigue—Lisinopril—systemic scleroderma	0.000361	0.0015	CcSEcCtD
Trifluoperazine—Hypersensitivity—Leflunomide—systemic scleroderma	0.00036	0.00149	CcSEcCtD
Trifluoperazine—Constipation—Lisinopril—systemic scleroderma	0.000359	0.00148	CcSEcCtD
Trifluoperazine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000357	0.00148	CcSEcCtD
Trifluoperazine—Nausea—Captopril—systemic scleroderma	0.000352	0.00146	CcSEcCtD
Trifluoperazine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00035	0.00145	CcSEcCtD
Trifluoperazine—Asthenia—Leflunomide—systemic scleroderma	0.00035	0.00145	CcSEcCtD
Trifluoperazine—Pancytopenia—Methotrexate—systemic scleroderma	0.000348	0.00144	CcSEcCtD
Trifluoperazine—Pruritus—Leflunomide—systemic scleroderma	0.000345	0.00143	CcSEcCtD
Trifluoperazine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000343	0.00142	CcSEcCtD
Trifluoperazine—Dizziness—Azathioprine—systemic scleroderma	0.000342	0.00141	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000337	0.0014	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000334	0.00138	CcSEcCtD
Trifluoperazine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000334	0.00138	CcSEcCtD
Trifluoperazine—Urticaria—Lisinopril—systemic scleroderma	0.000333	0.00138	CcSEcCtD
Trifluoperazine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000332	0.00138	CcSEcCtD
Trifluoperazine—Body temperature increased—Lisinopril—systemic scleroderma	0.000331	0.00137	CcSEcCtD
Trifluoperazine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000329	0.00136	CcSEcCtD
Trifluoperazine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000328	0.00136	CcSEcCtD
Trifluoperazine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000327	0.00135	CcSEcCtD
Trifluoperazine—Drowsiness—Methotrexate—systemic scleroderma	0.000326	0.00135	CcSEcCtD
Trifluoperazine—Rash—Azathioprine—systemic scleroderma	0.000326	0.00135	CcSEcCtD
Trifluoperazine—Dermatitis—Azathioprine—systemic scleroderma	0.000325	0.00135	CcSEcCtD
Trifluoperazine—Headache—Azathioprine—systemic scleroderma	0.000324	0.00134	CcSEcCtD
Trifluoperazine—Dizziness—Leflunomide—systemic scleroderma	0.000323	0.00134	CcSEcCtD
Trifluoperazine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000319	0.00132	CcSEcCtD
Trifluoperazine—ABCB1—lung—systemic scleroderma	0.000317	0.003	CbGeAlD
Trifluoperazine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000314	0.0013	CcSEcCtD
Trifluoperazine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000309	0.00128	CcSEcCtD
Trifluoperazine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000308	0.00127	CcSEcCtD
Trifluoperazine—Rash—Leflunomide—systemic scleroderma	0.000308	0.00127	CcSEcCtD
Trifluoperazine—Dermatitis—Leflunomide—systemic scleroderma	0.000307	0.00127	CcSEcCtD
Trifluoperazine—Nausea—Azathioprine—systemic scleroderma	0.000307	0.00127	CcSEcCtD
Trifluoperazine—Headache—Leflunomide—systemic scleroderma	0.000306	0.00127	CcSEcCtD
Trifluoperazine—Erythema—Prednisone—systemic scleroderma	0.000305	0.00126	CcSEcCtD
Trifluoperazine—Agranulocytosis—Methotrexate—systemic scleroderma	0.000305	0.00126	CcSEcCtD
Trifluoperazine—Asthenia—Lisinopril—systemic scleroderma	0.000301	0.00125	CcSEcCtD
Trifluoperazine—Pruritus—Lisinopril—systemic scleroderma	0.000297	0.00123	CcSEcCtD
Trifluoperazine—Rash—Mycophenolic acid—systemic scleroderma	0.000294	0.00121	CcSEcCtD
Trifluoperazine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000293	0.00121	CcSEcCtD
Trifluoperazine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000292	0.00121	CcSEcCtD
Trifluoperazine—Headache—Mycophenolic acid—systemic scleroderma	0.000292	0.00121	CcSEcCtD
Trifluoperazine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00029	0.0012	CcSEcCtD
Trifluoperazine—Nausea—Leflunomide—systemic scleroderma	0.00029	0.0012	CcSEcCtD
Trifluoperazine—Vision blurred—Prednisone—systemic scleroderma	0.000288	0.00119	CcSEcCtD
Trifluoperazine—Agitation—Prednisone—systemic scleroderma	0.00028	0.00116	CcSEcCtD
Trifluoperazine—Angioedema—Prednisone—systemic scleroderma	0.000279	0.00115	CcSEcCtD
Trifluoperazine—Dizziness—Lisinopril—systemic scleroderma	0.000277	0.00115	CcSEcCtD
Trifluoperazine—Nausea—Mycophenolic acid—systemic scleroderma	0.000277	0.00114	CcSEcCtD
Trifluoperazine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000271	0.00112	CcSEcCtD
Trifluoperazine—Rash—Lisinopril—systemic scleroderma	0.000264	0.00109	CcSEcCtD
Trifluoperazine—Convulsion—Prednisone—systemic scleroderma	0.000264	0.00109	CcSEcCtD
Trifluoperazine—Dermatitis—Lisinopril—systemic scleroderma	0.000264	0.00109	CcSEcCtD
Trifluoperazine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000264	0.00109	CcSEcCtD
Trifluoperazine—Headache—Lisinopril—systemic scleroderma	0.000263	0.00109	CcSEcCtD
Trifluoperazine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00026	0.00108	CcSEcCtD
Trifluoperazine—Erythema—Methotrexate—systemic scleroderma	0.000255	0.00106	CcSEcCtD
Trifluoperazine—Nausea—Lisinopril—systemic scleroderma	0.000249	0.00103	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000249	0.00103	CcSEcCtD
Trifluoperazine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000243	0.00101	CcSEcCtD
Trifluoperazine—Skin disorder—Prednisone—systemic scleroderma	0.000242	0.001	CcSEcCtD
Trifluoperazine—Vision blurred—Methotrexate—systemic scleroderma	0.00024	0.000995	CcSEcCtD
Trifluoperazine—Anorexia—Prednisone—systemic scleroderma	0.000237	0.000982	CcSEcCtD
Trifluoperazine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000232	0.000959	CcSEcCtD
Trifluoperazine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000231	0.000958	CcSEcCtD
Trifluoperazine—Headache—Mycophenolate mofetil—systemic scleroderma	0.00023	0.000953	CcSEcCtD
Trifluoperazine—Leukopenia—Methotrexate—systemic scleroderma	0.000228	0.000945	CcSEcCtD
Trifluoperazine—Insomnia—Prednisone—systemic scleroderma	0.000225	0.000932	CcSEcCtD
Trifluoperazine—Cough—Methotrexate—systemic scleroderma	0.000223	0.000921	CcSEcCtD
Trifluoperazine—Convulsion—Methotrexate—systemic scleroderma	0.000221	0.000914	CcSEcCtD
Trifluoperazine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000218	0.000903	CcSEcCtD
Trifluoperazine—Decreased appetite—Prednisone—systemic scleroderma	0.000216	0.000896	CcSEcCtD
Trifluoperazine—Fatigue—Prednisone—systemic scleroderma	0.000215	0.000889	CcSEcCtD
Trifluoperazine—Constipation—Prednisone—systemic scleroderma	0.000213	0.000881	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000208	0.000861	CcSEcCtD
Trifluoperazine—Skin disorder—Methotrexate—systemic scleroderma	0.000202	0.000837	CcSEcCtD
Trifluoperazine—Anorexia—Methotrexate—systemic scleroderma	0.000198	0.000821	CcSEcCtD
Trifluoperazine—Urticaria—Prednisone—systemic scleroderma	0.000198	0.000819	CcSEcCtD
Trifluoperazine—Body temperature increased—Prednisone—systemic scleroderma	0.000197	0.000815	CcSEcCtD
Trifluoperazine—Hypotension—Methotrexate—systemic scleroderma	0.000194	0.000805	CcSEcCtD
Trifluoperazine—Insomnia—Methotrexate—systemic scleroderma	0.000188	0.000779	CcSEcCtD
Trifluoperazine—Dyspnoea—Methotrexate—systemic scleroderma	0.000186	0.000768	CcSEcCtD
Trifluoperazine—Somnolence—Methotrexate—systemic scleroderma	0.000185	0.000766	CcSEcCtD
Trifluoperazine—Hypersensitivity—Prednisone—systemic scleroderma	0.000183	0.000759	CcSEcCtD
Trifluoperazine—Decreased appetite—Methotrexate—systemic scleroderma	0.000181	0.000749	CcSEcCtD
Trifluoperazine—Fatigue—Methotrexate—systemic scleroderma	0.000179	0.000743	CcSEcCtD
Trifluoperazine—Asthenia—Prednisone—systemic scleroderma	0.000179	0.000739	CcSEcCtD
Trifluoperazine—Pruritus—Prednisone—systemic scleroderma	0.000176	0.000729	CcSEcCtD
Trifluoperazine—Urticaria—Methotrexate—systemic scleroderma	0.000165	0.000684	CcSEcCtD
Trifluoperazine—Dizziness—Prednisone—systemic scleroderma	0.000165	0.000682	CcSEcCtD
Trifluoperazine—Body temperature increased—Methotrexate—systemic scleroderma	0.000165	0.000681	CcSEcCtD
Trifluoperazine—Rash—Prednisone—systemic scleroderma	0.000157	0.00065	CcSEcCtD
Trifluoperazine—Dermatitis—Prednisone—systemic scleroderma	0.000157	0.000649	CcSEcCtD
Trifluoperazine—Headache—Prednisone—systemic scleroderma	0.000156	0.000646	CcSEcCtD
Trifluoperazine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000153	0.000635	CcSEcCtD
Trifluoperazine—Asthenia—Methotrexate—systemic scleroderma	0.000149	0.000618	CcSEcCtD
Trifluoperazine—Nausea—Prednisone—systemic scleroderma	0.000148	0.000612	CcSEcCtD
Trifluoperazine—Pruritus—Methotrexate—systemic scleroderma	0.000147	0.000609	CcSEcCtD
Trifluoperazine—Dizziness—Methotrexate—systemic scleroderma	0.000138	0.00057	CcSEcCtD
Trifluoperazine—Rash—Methotrexate—systemic scleroderma	0.000131	0.000543	CcSEcCtD
Trifluoperazine—Dermatitis—Methotrexate—systemic scleroderma	0.000131	0.000543	CcSEcCtD
Trifluoperazine—Headache—Methotrexate—systemic scleroderma	0.00013	0.00054	CcSEcCtD
Trifluoperazine—Nausea—Methotrexate—systemic scleroderma	0.000124	0.000512	CcSEcCtD
Trifluoperazine—CALM3—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	3.37e-05	0.00108	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—RHOB—systemic scleroderma	3.36e-05	0.00108	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—RHOB—systemic scleroderma	3.35e-05	0.00108	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR ligand binding—EDN1—systemic scleroderma	3.34e-05	0.00107	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR ligand binding—EDN1—systemic scleroderma	3.33e-05	0.00107	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—BLK—systemic scleroderma	3.28e-05	0.00105	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—BLK—systemic scleroderma	3.28e-05	0.00105	CbGpPWpGaD
Trifluoperazine—CALM2—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	3.26e-05	0.00105	CbGpPWpGaD
Trifluoperazine—CALM1—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	3.26e-05	0.00105	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—RHOB—systemic scleroderma	3.16e-05	0.00101	CbGpPWpGaD
Trifluoperazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3.1e-05	0.000997	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—SMAD7—systemic scleroderma	3.1e-05	0.000994	CbGpPWpGaD
Trifluoperazine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3.05e-05	0.000981	CbGpPWpGaD
Trifluoperazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3.05e-05	0.000979	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—SMAD7—systemic scleroderma	3.02e-05	0.000971	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—SMAD7—systemic scleroderma	3.01e-05	0.000966	CbGpPWpGaD
Trifluoperazine—HTR6—GPCR downstream signaling—EDN1—systemic scleroderma	3.01e-05	0.000966	CbGpPWpGaD
Trifluoperazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	3e-05	0.000963	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—SMAD7—systemic scleroderma	2.99e-05	0.000962	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—SMAD7—systemic scleroderma	2.99e-05	0.000962	CbGpPWpGaD
Trifluoperazine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	2.99e-05	0.000961	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—HSPG2—systemic scleroderma	2.98e-05	0.000957	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—CSK—systemic scleroderma	2.88e-05	0.000924	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—RHOB—systemic scleroderma	2.84e-05	0.000912	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—TGFBI—systemic scleroderma	2.83e-05	0.000909	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—CTLA4—systemic scleroderma	2.78e-05	0.000891	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—RHOB—systemic scleroderma	2.75e-05	0.000882	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—RHOB—systemic scleroderma	2.75e-05	0.000882	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—TGFBI—systemic scleroderma	2.74e-05	0.00088	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—TGFBI—systemic scleroderma	2.74e-05	0.00088	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—EDN1—systemic scleroderma	2.73e-05	0.000877	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCR ligand binding—CCL2—systemic scleroderma	2.69e-05	0.000865	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—CTLA4—systemic scleroderma	2.68e-05	0.000862	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—CTLA4—systemic scleroderma	2.68e-05	0.000862	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCR ligand binding—CCL2—systemic scleroderma	2.68e-05	0.00086	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—SMAD7—systemic scleroderma	2.65e-05	0.000853	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—SMAD7—systemic scleroderma	2.61e-05	0.000839	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—SMAD7—systemic scleroderma	2.61e-05	0.000837	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.57e-05	0.000825	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—SMAD7—systemic scleroderma	2.56e-05	0.000824	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—SMAD7—systemic scleroderma	2.56e-05	0.000821	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR ligand binding—CCL2—systemic scleroderma	2.36e-05	0.000759	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CSK—systemic scleroderma	2.36e-05	0.000759	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—RHOB—systemic scleroderma	2.34e-05	0.000751	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—RHOB—systemic scleroderma	2.33e-05	0.000747	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR ligand binding—CCL2—systemic scleroderma	2.33e-05	0.000747	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IRF5—systemic scleroderma	2.32e-05	0.000747	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR ligand binding—CCL2—systemic scleroderma	2.32e-05	0.000745	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—HLA-DQB1—systemic scleroderma	2.29e-05	0.000734	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CSK—systemic scleroderma	2.29e-05	0.000734	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CSK—systemic scleroderma	2.29e-05	0.000734	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR ligand binding—CCL2—systemic scleroderma	2.28e-05	0.000734	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR ligand binding—CCL2—systemic scleroderma	2.28e-05	0.000732	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—HSPG2—systemic scleroderma	2.26e-05	0.000725	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IRF5—systemic scleroderma	2.25e-05	0.000722	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IRF5—systemic scleroderma	2.25e-05	0.000722	CbGpPWpGaD
Trifluoperazine—HTR1A—GPCR downstream signaling—EDN1—systemic scleroderma	2.23e-05	0.000715	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IRF8—systemic scleroderma	2.22e-05	0.000713	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CD247—systemic scleroderma	2.22e-05	0.000713	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—ITGAM—systemic scleroderma	2.22e-05	0.000713	CbGpPWpGaD
Trifluoperazine—HTR2C—GPCR downstream signaling—EDN1—systemic scleroderma	2.21e-05	0.000711	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	2.21e-05	0.00071	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	2.21e-05	0.00071	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—HSPG2—systemic scleroderma	2.21e-05	0.000708	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—HSPG2—systemic scleroderma	2.19e-05	0.000705	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—HSPG2—systemic scleroderma	2.18e-05	0.000702	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—HSPG2—systemic scleroderma	2.18e-05	0.000702	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—CSK—systemic scleroderma	2.18e-05	0.000701	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—SMAD7—systemic scleroderma	2.17e-05	0.000696	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—CD40LG—systemic scleroderma	2.16e-05	0.000693	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—ITGAM—systemic scleroderma	2.15e-05	0.00069	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CD247—systemic scleroderma	2.15e-05	0.00069	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CD247—systemic scleroderma	2.15e-05	0.00069	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IRF8—systemic scleroderma	2.15e-05	0.00069	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—ITGAM—systemic scleroderma	2.15e-05	0.00069	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IRF8—systemic scleroderma	2.15e-05	0.00069	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CSK—systemic scleroderma	2.13e-05	0.000684	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—MMP1—systemic scleroderma	2.12e-05	0.000682	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CSK—systemic scleroderma	2.12e-05	0.000681	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—CSK—systemic scleroderma	2.11e-05	0.000678	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—CSK—systemic scleroderma	2.11e-05	0.000678	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—SMAD7—systemic scleroderma	2.1e-05	0.000674	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—SMAD7—systemic scleroderma	2.1e-05	0.000674	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—CD40LG—systemic scleroderma	2.09e-05	0.000671	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—CD40LG—systemic scleroderma	2.09e-05	0.000671	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—TNFAIP3—systemic scleroderma	2.08e-05	0.000668	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—BLK—systemic scleroderma	2.05e-05	0.00066	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—MMP1—systemic scleroderma	2.05e-05	0.00066	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—MMP1—systemic scleroderma	2.05e-05	0.00066	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—RHOB—systemic scleroderma	2.05e-05	0.000659	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—CD247—systemic scleroderma	2.05e-05	0.000659	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—EDN1—systemic scleroderma	2.02e-05	0.000649	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—RHOB—systemic scleroderma	2.02e-05	0.000649	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—RHOB—systemic scleroderma	2.02e-05	0.000648	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—TNFAIP3—systemic scleroderma	2.01e-05	0.000646	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—TNFAIP3—systemic scleroderma	2.01e-05	0.000646	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—EDN1—systemic scleroderma	2.01e-05	0.000646	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—BLK—systemic scleroderma	1.99e-05	0.000639	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—BLK—systemic scleroderma	1.99e-05	0.000639	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—CD247—systemic scleroderma	1.98e-05	0.000637	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—CD247—systemic scleroderma	1.98e-05	0.000637	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—RHOB—systemic scleroderma	1.98e-05	0.000637	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—RHOB—systemic scleroderma	1.98e-05	0.000635	CbGpPWpGaD
Trifluoperazine—CALM3—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.97e-05	0.000634	CbGpPWpGaD
Trifluoperazine—DRD2—GPCR downstream signaling—EDN1—systemic scleroderma	1.95e-05	0.000628	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.95e-05	0.000625	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—HSPG2—systemic scleroderma	1.94e-05	0.000622	CbGpPWpGaD
Trifluoperazine—HTR2A—GPCR downstream signaling—EDN1—systemic scleroderma	1.92e-05	0.000618	CbGpPWpGaD
Trifluoperazine—HRH1—GPCR downstream signaling—EDN1—systemic scleroderma	1.92e-05	0.000616	CbGpPWpGaD
Trifluoperazine—CALM1—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.91e-05	0.000613	CbGpPWpGaD
Trifluoperazine—CALM2—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.91e-05	0.000613	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—HSPG2—systemic scleroderma	1.9e-05	0.000612	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—HSPG2—systemic scleroderma	1.9e-05	0.000611	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—HSPG2—systemic scleroderma	1.89e-05	0.000608	CbGpPWpGaD
Trifluoperazine—CHRM2—GPCR downstream signaling—EDN1—systemic scleroderma	1.89e-05	0.000606	CbGpPWpGaD
Trifluoperazine—ADRA1A—GPCR downstream signaling—EDN1—systemic scleroderma	1.88e-05	0.000605	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—HSPG2—systemic scleroderma	1.87e-05	0.000601	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CSK—systemic scleroderma	1.87e-05	0.000601	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—CCL2—systemic scleroderma	1.87e-05	0.0006	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—HSPG2—systemic scleroderma	1.87e-05	0.000599	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CSK—systemic scleroderma	1.84e-05	0.000591	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CSK—systemic scleroderma	1.84e-05	0.00059	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—HSPG2—systemic scleroderma	1.83e-05	0.000588	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—HSPG2—systemic scleroderma	1.83e-05	0.000588	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CSK—systemic scleroderma	1.81e-05	0.00058	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CSK—systemic scleroderma	1.8e-05	0.000579	CbGpPWpGaD
Trifluoperazine—UGT1A4—Metabolism—NOS3—systemic scleroderma	1.79e-05	0.000576	CbGpPWpGaD
Trifluoperazine—XDH—Metabolism—NOS3—systemic scleroderma	1.79e-05	0.000576	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—EDN1—systemic scleroderma	1.77e-05	0.00057	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—EDN1—systemic scleroderma	1.75e-05	0.000561	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—EDN1—systemic scleroderma	1.74e-05	0.00056	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—EDN1—systemic scleroderma	1.71e-05	0.000551	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—EDN1—systemic scleroderma	1.71e-05	0.000549	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CTLA4—systemic scleroderma	1.68e-05	0.000541	CbGpPWpGaD
Trifluoperazine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.68e-05	0.00054	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—RHOB—systemic scleroderma	1.68e-05	0.000539	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CTLA4—systemic scleroderma	1.63e-05	0.000523	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CTLA4—systemic scleroderma	1.63e-05	0.000523	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—RHOB—systemic scleroderma	1.62e-05	0.000521	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—RHOB—systemic scleroderma	1.62e-05	0.000521	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—EDN1—systemic scleroderma	1.61e-05	0.000518	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—HSPG2—systemic scleroderma	1.58e-05	0.000508	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—NOS3—systemic scleroderma	1.54e-05	0.000494	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—HSPG2—systemic scleroderma	1.53e-05	0.000491	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—HSPG2—systemic scleroderma	1.53e-05	0.000491	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CSK—systemic scleroderma	1.53e-05	0.000491	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—NOS3—systemic scleroderma	1.49e-05	0.000478	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—NOS3—systemic scleroderma	1.49e-05	0.000478	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CSK—systemic scleroderma	1.48e-05	0.000475	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CSK—systemic scleroderma	1.48e-05	0.000475	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—EDN1—systemic scleroderma	1.45e-05	0.000466	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—CTGF—systemic scleroderma	1.43e-05	0.00046	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.43e-05	0.00046	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—EDN1—systemic scleroderma	1.4e-05	0.00045	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—EDN1—systemic scleroderma	1.4e-05	0.00045	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—CTGF—systemic scleroderma	1.39e-05	0.000445	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—CTGF—systemic scleroderma	1.39e-05	0.000445	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—HLA-DQB1—systemic scleroderma	1.39e-05	0.000445	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—CCL2—systemic scleroderma	1.38e-05	0.000444	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—CCL2—systemic scleroderma	1.37e-05	0.000442	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—HLA-DQB1—systemic scleroderma	1.34e-05	0.000431	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—HLA-DQB1—systemic scleroderma	1.34e-05	0.000431	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL1A—systemic scleroderma	1.32e-05	0.000423	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CD40LG—systemic scleroderma	1.31e-05	0.00042	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL1A—systemic scleroderma	1.27e-05	0.000409	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL1A—systemic scleroderma	1.27e-05	0.000409	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CD40LG—systemic scleroderma	1.27e-05	0.000407	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CD40LG—systemic scleroderma	1.27e-05	0.000407	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—CCL2—systemic scleroderma	1.21e-05	0.00039	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EDN1—systemic scleroderma	1.19e-05	0.000384	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—CCL2—systemic scleroderma	1.19e-05	0.000383	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—CCL2—systemic scleroderma	1.19e-05	0.000383	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EDN1—systemic scleroderma	1.19e-05	0.000382	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—CCL2—systemic scleroderma	1.17e-05	0.000376	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—CCL2—systemic scleroderma	1.17e-05	0.000375	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—HSPG2—systemic scleroderma	1.14e-05	0.000368	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—CCL2—systemic scleroderma	1.1e-05	0.000354	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—CTGF—systemic scleroderma	1.09e-05	0.000349	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EDN1—systemic scleroderma	1.05e-05	0.000337	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EDN1—systemic scleroderma	1.03e-05	0.000331	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EDN1—systemic scleroderma	1.03e-05	0.000331	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—TGFB1—systemic scleroderma	1.02e-05	0.000327	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EDN1—systemic scleroderma	1.01e-05	0.000325	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EDN1—systemic scleroderma	1.01e-05	0.000324	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—CCL2—systemic scleroderma	9.91e-06	0.000318	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—TGFB1—systemic scleroderma	9.84e-06	0.000316	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—TGFB1—systemic scleroderma	9.84e-06	0.000316	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—NOS3—systemic scleroderma	9.83e-06	0.000316	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—CCL2—systemic scleroderma	9.58e-06	0.000308	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—CCL2—systemic scleroderma	9.58e-06	0.000308	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CTGF—systemic scleroderma	8.67e-06	0.000279	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EDN1—systemic scleroderma	8.56e-06	0.000275	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EDN1—systemic scleroderma	8.28e-06	0.000266	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EDN1—systemic scleroderma	8.28e-06	0.000266	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CCL2—systemic scleroderma	8.16e-06	0.000262	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CCL2—systemic scleroderma	8.12e-06	0.000261	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—MMP9—systemic scleroderma	7.88e-06	0.000253	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—NOS3—systemic scleroderma	7.45e-06	0.000239	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—NOS3—systemic scleroderma	7.27e-06	0.000234	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—NOS3—systemic scleroderma	7.24e-06	0.000232	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—NOS3—systemic scleroderma	7.21e-06	0.000231	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—NOS3—systemic scleroderma	7.21e-06	0.000231	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CCL2—systemic scleroderma	7.17e-06	0.00023	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CCL2—systemic scleroderma	7.05e-06	0.000226	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CCL2—systemic scleroderma	7.04e-06	0.000226	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CCL2—systemic scleroderma	6.92e-06	0.000222	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CCL2—systemic scleroderma	6.9e-06	0.000222	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL1B—systemic scleroderma	6.87e-06	0.000221	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL1B—systemic scleroderma	6.64e-06	0.000213	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL1B—systemic scleroderma	6.64e-06	0.000213	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—TGFB1—systemic scleroderma	6.5e-06	0.000209	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NOS3—systemic scleroderma	6.39e-06	0.000205	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NOS3—systemic scleroderma	6.28e-06	0.000202	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NOS3—systemic scleroderma	6.27e-06	0.000201	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—NOS3—systemic scleroderma	6.24e-06	0.0002	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NOS3—systemic scleroderma	6.17e-06	0.000198	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NOS3—systemic scleroderma	6.15e-06	0.000198	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—NOS3—systemic scleroderma	6.03e-06	0.000194	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—NOS3—systemic scleroderma	6.03e-06	0.000194	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CCL2—systemic scleroderma	5.85e-06	0.000188	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MMP9—systemic scleroderma	5.84e-06	0.000187	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MMP9—systemic scleroderma	5.81e-06	0.000187	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CCL2—systemic scleroderma	5.66e-06	0.000182	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CCL2—systemic scleroderma	5.66e-06	0.000182	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NOS3—systemic scleroderma	5.22e-06	0.000168	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MMP9—systemic scleroderma	5.12e-06	0.000165	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NOS3—systemic scleroderma	5.05e-06	0.000162	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NOS3—systemic scleroderma	5.05e-06	0.000162	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MMP9—systemic scleroderma	5.04e-06	0.000162	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MMP9—systemic scleroderma	5.03e-06	0.000162	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MMP9—systemic scleroderma	4.95e-06	0.000159	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MMP9—systemic scleroderma	4.94e-06	0.000159	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—TGFB1—systemic scleroderma	4.93e-06	0.000158	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TGFB1—systemic scleroderma	4.81e-06	0.000155	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TGFB1—systemic scleroderma	4.79e-06	0.000154	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—TGFB1—systemic scleroderma	4.76e-06	0.000153	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—TGFB1—systemic scleroderma	4.76e-06	0.000153	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—NOS3—systemic scleroderma	4.73e-06	0.000152	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TGFB1—systemic scleroderma	4.22e-06	0.000136	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MMP9—systemic scleroderma	4.19e-06	0.000134	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TGFB1—systemic scleroderma	4.16e-06	0.000133	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TGFB1—systemic scleroderma	4.15e-06	0.000133	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TGFB1—systemic scleroderma	4.08e-06	0.000131	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TGFB1—systemic scleroderma	4.07e-06	0.000131	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MMP9—systemic scleroderma	4.05e-06	0.00013	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MMP9—systemic scleroderma	4.05e-06	0.00013	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—NOS3—systemic scleroderma	3.77e-06	0.000121	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TGFB1—systemic scleroderma	3.45e-06	0.000111	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TGFB1—systemic scleroderma	3.34e-06	0.000107	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TGFB1—systemic scleroderma	3.34e-06	0.000107	CbGpPWpGaD
